Trenchant BioSystems released internal and third‑party data for its AutoCell cell‑and‑gene therapy (CGT) manufacturing prototype, saying the platform can cut vein‑to‑vein timelines from ~6 weeks to 2.5 days, increase gene‑modified cell yields 7‑fold, and reduce costs by up to 80%. The company validated key unit operations—washing, selection, activation and transduction—on five fresh apheresis collections and reported external validation of core steps by Invetech. Trenchant positions AutoCell as an automated manufacturing and QC platform capable of producing clinical doses with less starting material and faster release testing. If external peer‑reviewed data confirm performance and reproducibility in GMP settings, the platform could materially change CGT scalability economics and support broader patient access.